TY - JOUR
T1 - Cost-effectiveness of hepatitis C screening and treatment in low-income, primarily hispanic baby boomers
AU - Hollenbeak, Christopher S.
AU - Rochat, Andrea
AU - Hollenbeak, Asher C.
AU - Choi, Aro N.
AU - Gutierrez, Julio
AU - Turner, Barbara J.
N1 - Publisher Copyright:
© Meharry Medical College.
PY - 2019/8
Y1 - 2019/8
N2 - The cost- effectiveness of hepatitis C virus (HCV) screening and treatment was examined in low-income, primarily Hispanic baby boomers born 1945- 1965 using a Markov model of the natural history of HCV. The model was parameterized using costs and diagnostic data from 2008- 2016 and from literature on disease progression and effectiveness of screening and treatment using direct acting anti- viral (DAA) therapy. The incremental cost- effectiveness ratio (ICER) was computed from the perspective of Medicare as payer, calculated over 20 years, and discounted at 3% per year. In the base case, HCV screening cost $3,334 versus $3,797 for no screening, and yielded more quality- adjusted life years (QALYs; 14.08 vs 13.96, respectively). The ICER for screening was still less than $20,000 per additional QALY with drug costs up to $100,000. Among low-income Hispanics, HCV screening was less costly for Medicare and more effective than no screening under most assumptions. This analysis supports investment in screening and treatment in Hispanics.
AB - The cost- effectiveness of hepatitis C virus (HCV) screening and treatment was examined in low-income, primarily Hispanic baby boomers born 1945- 1965 using a Markov model of the natural history of HCV. The model was parameterized using costs and diagnostic data from 2008- 2016 and from literature on disease progression and effectiveness of screening and treatment using direct acting anti- viral (DAA) therapy. The incremental cost- effectiveness ratio (ICER) was computed from the perspective of Medicare as payer, calculated over 20 years, and discounted at 3% per year. In the base case, HCV screening cost $3,334 versus $3,797 for no screening, and yielded more quality- adjusted life years (QALYs; 14.08 vs 13.96, respectively). The ICER for screening was still less than $20,000 per additional QALY with drug costs up to $100,000. Among low-income Hispanics, HCV screening was less costly for Medicare and more effective than no screening under most assumptions. This analysis supports investment in screening and treatment in Hispanics.
UR - http://www.scopus.com/inward/record.url?scp=85072144507&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072144507&partnerID=8YFLogxK
U2 - 10.1353/hpu.2019.0073
DO - 10.1353/hpu.2019.0073
M3 - Article
C2 - 31422988
AN - SCOPUS:85072144507
SN - 1049-2089
VL - 30
SP - 1053
EP - 1067
JO - Journal of Health Care for the Poor and Underserved
JF - Journal of Health Care for the Poor and Underserved
IS - 3
ER -
